RACHELLE DOODY to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications RACHELLE DOODY has written about Randomized Controlled Trials as Topic.
Connection Strength
0.467
-
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44.
Score: 0.077
-
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement. 2013 May; 9(3):338-45.
Score: 0.073
-
Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies. Neurodegener Dis. 2012; 10(1-4):170-4.
Score: 0.070
-
Donepezil treatment of patients with MCI: a 48-week randomized, placebo- controlled trial. Neurology. 2009 Nov 03; 73(18):1514-5; author reply 1515-6.
Score: 0.060
-
Dimebon as a potential therapy for Alzheimer's disease. CNS Spectr. 2009 Aug; 14(8 Suppl 7):14-6; discussion 16-8.
Score: 0.059
-
Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):260-7.
Score: 0.058
-
Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2004; 18(2):227-32.
Score: 0.041
-
Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology. 1999; 45 Suppl 1:23-32.
Score: 0.028